390 related articles for article (PubMed ID: 33552465)
1. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.
Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
Ther Adv Endocrinol Metab; 2021; 12():2042018821989238. PubMed ID: 33552465
[TBL] [Abstract][Full Text] [Related]
2. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based therapies in type 2 diabetes mellitus.
Chia CW; Egan JM
J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
[TBL] [Abstract][Full Text] [Related]
4. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.
Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
Yang S; Zhao L; He W; Mi Y
Drugs; 2022 Sep; 82(14):1469-1480. PubMed ID: 36129662
[TBL] [Abstract][Full Text] [Related]
7. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H; Chiovato L; Nappi RE
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
9. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Ferjan S; Janez A; Jensterle M
Endocr Pract; 2018 Jan; 24(1):69-77. PubMed ID: 29144805
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
13. Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.
Etrusco A; Mikuš M; D'Amato A; Barra F; Planinić P; Goluža T; Buzzaccarini G; Marušić J; Tešanović M; Laganà AS
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540265
[TBL] [Abstract][Full Text] [Related]
14. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
18. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome.
Öztürk B; Gürbüz AS; Durak ZE; Öztürk HS
Gynecol Endocrinol; 2019 Feb; 35(2):138-141. PubMed ID: 30394149
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
Niafar M; Pourafkari L; Porhomayon J; Nader N
Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
